Zoetis Inc. · NYSE (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-12-12$178.84 RISE2025-04-08$144.41 PEAK2025-06-03$170.30 173d | -19.3% 117d | Missed | Missed | — | — | +17.9% 56d | Missed |
DROP2024-02-28$199.94 RISE2024-06-25$167.98 PEAK2024-09-18$196.48 203d | -16.0% 118d | Missed | Missed | — | — | +17.0% 85d | Missed |
DROP2023-12-14$200.09 RISE2024-04-22$145.54 PEAK2024-07-16$182.91 215d | -27.3% 130d | Missed | Missed | — | — | +25.7% 85d | Missed |
DROP2023-08-29$192.77 RISE2023-11-01$151.44 PEAK2023-12-14$200.09 107d | -21.4% 64d | Missed | Missed | — | — | +32.1% 43d | Missed |
DROP2022-08-12$175.67 RISE2022-12-20$142.47 PEAK2023-02-15$175.02 187d | -18.9% 130d | 2022-10-17 $149.79 | 2023-01-11 $157.90 | 56Quality on Sale | 45Watch | +22.8% 57d | +5.4% Held 86d |
DROP2022-07-29$182.55 RISE2022-11-03$131.14 PEAK2023-01-26$168.24 181d | -28.2% 97d | 2022-10-17 $149.79 | 2023-01-11 $157.90 | 56Quality on Sale | 45Watch | +28.3% 84d | +5.4% Duplicate trade Held 86d |
DROP2022-02-09$202.29 RISE2022-06-13$155.97 PEAK2022-07-29$182.55 170d | -22.9% 124d | Missed | Missed | — | — | +17.0% 46d | Missed |
DROP2020-11-04$174.35 RISE2021-03-04$144.00 PEAK2021-05-28$176.68 205d | -17.4% 120d | Missed | Missed | — | — | +22.7% 85d | Missed |
DROP2020-02-13$144.94 RISE2020-03-23$92.66 PEAK2020-06-03$142.53 111d | -36.1% 39d | Missed | Missed | — | — | +53.8% 72d | Missed |
FedEx upgraded, Dollar General downgraded: Wall Street's top analyst calls
Pre-Market Stock Futures: Futures are trading higher as we hit the mid-week point, as the technology-led rally continues to spiral higher. While the major indices finished the day mixed, the technology-heavy Nasdaq led the way once again, closing at a new record high of 26,656, up 1.19%, while the S&P 500 also set a new ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Agilent, Dollar General, FedEx, GE Aerospace, Hershey, Intuit, SanDisk, Workday, Zscaler, and More
The health care sector's most oversold stocks are a buying opportunity due to undervalued companies. RSI indicator shows potential for short-term gains.
Barronâs Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Read the full list here.
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
The Moat Index outperformed through February before a sharp MarchâMay selloff erased its lead. Read more here.
Get the latest analyst rating changes for top companies on Wall Street, including upgrades and downgrades. View complete details at Benzinga.
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $105 to $95.
Zoetis (NYSE:ZTS) is facing an investigation into potential securities fraud tied to a sharp guidance cut following earlier positive comments about its outlook. The probe focuses on whether prior statements about growth prospects were misleading and if investors received a full and timely picture of the company’s expectations. This development raises fresh questions about management credibility, disclosure practices, and possible legal and regulatory consequences for Zoetis. Zoetis focuses...
Zoetis (NYSE:ZTS) is facing an investigation into potential securities fraud tied to a sharp guidance cut following earlier positive comments about its outlook. The probe focuses on whether prior statements about growth prospects were misleading and if investors received a full and timely picture of the company’s expectations. This development raises fresh questions about management credibility, disclosure practices, and possible legal and regulatory consequences for Zoetis. Zoetis focuses...
PARSIPPANY, N.J., May 21, 2026--Zoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences.
While the rest of the market has been chasing AI, Michael Burry spent his Monday evening on Substack explaining why he has been buying the stocks everyone else is ignoring. He has a name for what he is seeing. And it is not a phrase Wall Street has used before. Burry disclosed in a Substack post on ...
While the rest of the market has been chasing AI, Michael Burry spent his Monday evening on Substack explaining why he has been buying the stocks everyone else is ignoring. He has a name for what he is seeing. And it is not a phrase Wall Street has used before. Burry disclosed in a Substack post on ...
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
PARSIPPANY, N.J., May 20, 2026--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, July 20, 2026.
The average S&P 500 stock gained 35% in the year leading up to the index's most recent all-time closing high made last Thursday (5/14).
https://www.fda.gov/animal-veterinary/cvm-updates/fda-issues-emergency-use-authorization-over-counter-injectable-drug-new-world-screwworm-dairy-cattle
Zoetis offers a strong dividend growth history and top profitability, with a 1.64% yield and P/E of 12.01, making it an attractive value play for income-focused investors.
Citigroup analyst Daniel Grosslight maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $145 to $112.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ZTS | -31.95% | -39.76% | -38.25% | -53.93% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -34.92% | -34.04% | -34.81% | -66.62% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 19.32M | $2.28B | 0.08% | Trimmed-2.4% | 2026-03-31 |
| Wellington | fundamental | 10.15M | $1.20B | 0.22% | Trimmed-10.9% | 2026-03-31 |
| CapResearch | fundamental | 1.41M | $166.51M | 0.03% | Trimmed-1.4% | 2026-03-31 |
| FidelityFMR | fundamental | 562.6K | $66.51M | 0.00% | Added+28.1% | 2026-03-31 |
| RenTech | quant | 252.0K | $29.79M | 0.05% | Trimmed-40.7% | 2026-03-31 |
| TwoSigma | quant | 142.3K | $16.82M | 0.01% | Added+28.5% | 2026-03-31 |
| DEShaw | quant | 75.1K | $8.88M | 0.01% | Trimmed-93.8% | 2026-03-31 |
| Bridgewater | macro | 50.7K | $6.00M | 0.03% | Trimmed-72.2% | 2026-03-31 |
| TRowePrice | fundamental | 1.02M | $120.35K | 0.01% | Trimmed-21.2% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | Stetter Mark | Director | M Option exercise(deriv) | 1,572 | — | — |
| 2026-05-26 | Stetter Mark | Director | M Option exercise | 1,572 | — | — |
| 2026-05-21 | PARENT LOUISE M | Director | M Option exercise(deriv) | 10,187 | — | +$0 |
| 2026-05-21 | PARENT LOUISE M | Director | M Option exercise(deriv) | 1,944 | — | +$0 |
| 2026-05-21 | PARENT LOUISE M | Director | M Option exercise | 10,186 | — | — |
| 2026-05-21 | PARENT LOUISE M | Director | M Option exercise | 1,944 | — | — |
| 2026-05-13 | Bisaro Paul | Director | P Open-market purchase | 2,000 | $75.88 | +$151.8K |
| 2026-05-13 | DAMELIO FRANK A | Director | P Open-market purchase | 6,650 | $75.39 | +$501.3K |
| 2026-05-12 | MCCALLISTER MICHAEL B | Director | P Open-market purchase | 3,000 | $77.76 | +$233.3K |
| 2026-05-01 | Esch Kevin | Executive Vice President | M Option exercise(deriv) | 260 | — | — |
| 2026-05-01 | Esch Kevin | Executive Vice President | F Tax withholding | 75 | $114.97 | −$8.6K |
| 2026-05-01 | Esch Kevin | Executive Vice President | M Option exercise | 259 | — | — |
| 2026-04-13 | Sarbaugh Keith | Executive Vice President | A Grant / award(deriv) | 231 | $39.64 | +$9.1K |
| 2026-04-13 | Joseph Wetteny | Chief Financial Officer | A Grant / award(deriv) | 874 | $39.64 | +$34.6K |
| 2026-04-13 | Driscoll Rimma | Executive Vice President | A Grant / award(deriv) | 26 | $39.64 | +$1.0K |
| 2026-04-13 | PECK KRISTIN C | Chief Executive Officer | A Grant / award(deriv) | 2,777 | $39.64 | +$110.1K |
| 2026-04-13 | Esch Kevin | Executive Vice President | A Grant / award(deriv) | 1 | $39.64 | +$55 |
| 2026-04-13 | Ferran Astorga Jeannette | Executive Vice President | A Grant / award(deriv) | 5 | $39.64 | +$198 |
| 2026-04-13 | Lagano Roxanne | Executive Vice President | A Grant / award(deriv) | 551 | $39.64 | +$21.8K |
| 2026-04-13 | FULLER JULIE | Executive Vice President | A Grant / award(deriv) | 551 | $39.64 | +$21.8K |
| 2026-04-01 | Sarbaugh Keith | Executive Vice President | M Option exercise(deriv) | 1,528 | — | — |
| 2026-04-01 | Sarbaugh Keith | Executive Vice President | F Tax withholding | 524 | $118.21 | −$61.9K |
| 2026-04-01 | Sarbaugh Keith | Executive Vice President | M Option exercise | 1,528 | — | — |
| 2026-03-31 | Lagano Roxanne | Executive Vice President | A Grant / award(deriv) | 1,266 | $38.20 | +$48.4K |
| 2026-03-31 | Sarbaugh Keith | Executive Vice President | A Grant / award(deriv) | 627 | $38.20 | +$23.9K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 1.86 | — | — |
| 2026-05-07 | 1.54 | 1.42 | -7.59% |
| 2026-02-12 | 1.40 | 1.48 | +5.48% |
| 2025-11-04 | 1.62 | 1.70 | +4.83% |
| 2025-08-05 | 1.52 | 1.61 | +5.80% |
| 2025-05-06 | 1.40 | 1.48 | +5.79% |
| 2025-02-13 | 1.36 | 1.40 | +2.84% |
| 2024-11-04 | 1.46 | 1.58 | +8.03% |
| 2024-08-06 | 1.48 | 1.56 | +5.30% |
| 2024-05-02 | 1.27 | 1.31 | +3.48% |
| 2024-02-13 | 1.32 | 1.24 | -5.87% |
| 2023-11-02 | 1.36 | 1.36 | +0.36% |
| 2023-08-08 | 1.31 | 1.41 | +8.01% |
| 2023-05-04 | 1.25 | 1.31 | +4.53% |
| 2023-02-14 | 1.15 | 1.15 | +0.26% |
| 2022-11-03 | 1.24 | 1.21 | -2.09% |